Cystine transporter SLC7A11/xCT in cancer: ferroptosis, nutrient dependency, and cancer therapy
Abstract The cystine/glutamate antiporter SLC7A11 (also commonly known as xCT) functions to import cystine for glutathione biosynthesis and antioxidant defense and is overexpressed in multiple human cancers. Recent studies revealed that SLC7A11 overexpression promotes tumor growth partly through sup...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Oxford University Press
2020-10-01
|
| Series: | Protein & Cell |
| Subjects: | |
| Online Access: | https://doi.org/10.1007/s13238-020-00789-5 |
| _version_ | 1827852334186627072 |
|---|---|
| author | Pranavi Koppula Li Zhuang Boyi Gan |
| author_facet | Pranavi Koppula Li Zhuang Boyi Gan |
| author_sort | Pranavi Koppula |
| collection | DOAJ |
| description | Abstract The cystine/glutamate antiporter SLC7A11 (also commonly known as xCT) functions to import cystine for glutathione biosynthesis and antioxidant defense and is overexpressed in multiple human cancers. Recent studies revealed that SLC7A11 overexpression promotes tumor growth partly through suppressing ferroptosis, a form of regulated cell death induced by excessive lipid peroxidation. However, cancer cells with high expression of SLC7A11 (SLC7A11high) also have to endure the significant cost associated with SLC7A11-mediated metabolic reprogramming, leading to glucose- and glutamine-dependency in SLC7A11high cancer cells, which presents potential metabolic vulnerabilities for therapeutic targeting in SLC7A11high cancer. In this review, we summarize diverse regulatory mechanisms of SLC7A11 in cancer, discuss ferroptosis-dependent and -independent functions of SLC7A11 in promoting tumor development, explore the mechanistic basis of SLC7A11-induced nutrient dependency in cancer cells, and conceptualize therapeutic strategies to target SLC7A11 in cancer treatment. This review will provide the foundation for further understanding SLC7A11 in ferroptosis, nutrient dependency, and tumor biology and for developing novel effective cancer therapies. |
| first_indexed | 2024-03-12T10:49:15Z |
| format | Article |
| id | doaj.art-16e866b8f7af4188bc3291018867f342 |
| institution | Directory Open Access Journal |
| issn | 1674-800X 1674-8018 |
| language | English |
| last_indexed | 2024-03-12T10:49:15Z |
| publishDate | 2020-10-01 |
| publisher | Oxford University Press |
| record_format | Article |
| series | Protein & Cell |
| spelling | doaj.art-16e866b8f7af4188bc3291018867f3422023-09-02T07:11:44ZengOxford University PressProtein & Cell1674-800X1674-80182020-10-0112859962010.1007/s13238-020-00789-5Cystine transporter SLC7A11/xCT in cancer: ferroptosis, nutrient dependency, and cancer therapyPranavi Koppula0Li Zhuang1Boyi Gan2Department of Experimental Radiation Oncology, The University of Texas MD Anderson Cancer CenterDepartment of Experimental Radiation Oncology, The University of Texas MD Anderson Cancer CenterDepartment of Experimental Radiation Oncology, The University of Texas MD Anderson Cancer CenterAbstract The cystine/glutamate antiporter SLC7A11 (also commonly known as xCT) functions to import cystine for glutathione biosynthesis and antioxidant defense and is overexpressed in multiple human cancers. Recent studies revealed that SLC7A11 overexpression promotes tumor growth partly through suppressing ferroptosis, a form of regulated cell death induced by excessive lipid peroxidation. However, cancer cells with high expression of SLC7A11 (SLC7A11high) also have to endure the significant cost associated with SLC7A11-mediated metabolic reprogramming, leading to glucose- and glutamine-dependency in SLC7A11high cancer cells, which presents potential metabolic vulnerabilities for therapeutic targeting in SLC7A11high cancer. In this review, we summarize diverse regulatory mechanisms of SLC7A11 in cancer, discuss ferroptosis-dependent and -independent functions of SLC7A11 in promoting tumor development, explore the mechanistic basis of SLC7A11-induced nutrient dependency in cancer cells, and conceptualize therapeutic strategies to target SLC7A11 in cancer treatment. This review will provide the foundation for further understanding SLC7A11 in ferroptosis, nutrient dependency, and tumor biology and for developing novel effective cancer therapies.https://doi.org/10.1007/s13238-020-00789-5SLC7A11xCTcystinecysteineferroptosisnutrient dependency |
| spellingShingle | Pranavi Koppula Li Zhuang Boyi Gan Cystine transporter SLC7A11/xCT in cancer: ferroptosis, nutrient dependency, and cancer therapy Protein & Cell SLC7A11 xCT cystine cysteine ferroptosis nutrient dependency |
| title | Cystine transporter SLC7A11/xCT in cancer: ferroptosis, nutrient dependency, and cancer therapy |
| title_full | Cystine transporter SLC7A11/xCT in cancer: ferroptosis, nutrient dependency, and cancer therapy |
| title_fullStr | Cystine transporter SLC7A11/xCT in cancer: ferroptosis, nutrient dependency, and cancer therapy |
| title_full_unstemmed | Cystine transporter SLC7A11/xCT in cancer: ferroptosis, nutrient dependency, and cancer therapy |
| title_short | Cystine transporter SLC7A11/xCT in cancer: ferroptosis, nutrient dependency, and cancer therapy |
| title_sort | cystine transporter slc7a11 xct in cancer ferroptosis nutrient dependency and cancer therapy |
| topic | SLC7A11 xCT cystine cysteine ferroptosis nutrient dependency |
| url | https://doi.org/10.1007/s13238-020-00789-5 |
| work_keys_str_mv | AT pranavikoppula cystinetransporterslc7a11xctincancerferroptosisnutrientdependencyandcancertherapy AT lizhuang cystinetransporterslc7a11xctincancerferroptosisnutrientdependencyandcancertherapy AT boyigan cystinetransporterslc7a11xctincancerferroptosisnutrientdependencyandcancertherapy |